title: Response to "Should intralesional bleomycin be used in the treatment of HPV-related genital disease in the immunocompromised host?".
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Rachel.Gormley@uphs.upenn.edu.
authors.forename: Rachel H
authors.initials: RH
authors.lastname: Gormley
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: Glen H
authors.initials: GH
authors.lastname: Crawford
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: Carrie L
authors.initials: CL
authors.lastname: Kovarik
mesh_terms: D052685:Alphapapillomavirus; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D030361:Papillomavirus Infections / Q000628:therapy*; D010412:Penile Neoplasms / Q000628:therapy*; D014625:Vaginal Neoplasms / Q000628:therapy*; D014846:Vulvar Neoplasms / Q000628:therapy*; D014860:Warts / Q000628:therapy*